A significant proportion of patients with chronic hepatitis B who are candidates for antiviral treatment are untreated: A region-wide survey in italy

Journal of Clinical Gastroenterology

Volumn 43, Issue 10, 2009, Pages 1001-1007

  Giannini, Edoardo G ^a   Torre, Francesco ^b   Basso, Monica ^c   Feasi, Marcello ^e   Boni, Silvia ⁱ   Grasso, Alessandro ^j   De Leo, Pasqualina ^k   Dodi, Ferdinando ^f   Marazzi, Maria Grazia ^g   Azzola, Emilio ^l   Bartolacci, Valentina ^m   Percario, Gianfranco ^h   Beltrame, Andrea ^d   Borro, Paolo ^d   Savarino, Vincenzo ^a   Picciotto, Antonino ^c  

^a Cattedra di Gastroenterologia   (Italy)

^b Cattedra di Semeiotica Medica   (Italy)

^c Dipartimento di Medicina Interna   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e GALLIERA HOSPITAL   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

^g G GASLINI INSTITUTE   (Italy)

^h Ospedale San Carlo   (Italy)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

^j Divisione di Medicina Generale II

^k San Paolo Hospital   (Italy)

^l Division of Gastroenterology   (Italy)

^m SANTA CORONA HOSPITAL   (Italy)

more..

Author keywords

Guidelines; Hepatitis B virus; Treatment

Indexed keywords

HEPATITIS B(E) ANTIGEN; VIRUS DNA; ANTIVIRUS AGENT;

ADOLESCENT; ADULT; AGED; ALGORITHM; ARTICLE; CHILD; CHRONIC HEPATITIS; CLINICAL PRACTICE; DISEASE COURSE; FEMALE; HEALTH SURVEY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; ITALY; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VIREMIA; VIRUS DETECTION; VIRUS HEPATITIS; BLOOD; FACTUAL DATABASE; FOLLOW UP; MIDDLE AGED; PRESCHOOL CHILD; VIROLOGY;

ADOLESCENT; ADULT; AGED; ALGORITHMS; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; ITALY; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; YOUNG ADULT;

EID: 74949135174     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31818e876f     Document Type: Article

References (34)

1. Lee W. Hepatitis B virus infection. N Engl J Med. 1997;337: 1733-1745.
2. Hoofnagle JH, Doo E, Liang TJ, et al.. Management of hepatitis B: summary of a clinical research workshop. Hepatology. 2007;45:1056-1075.
3. Perz JF, Armstrong GL, Farrington LA, et al.. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006; 45:529-538.
4. Bonanni P, Crovari P. Success stories in the implementation of universal hepatitis B vaccination: an update on Italy. Vaccine. 1998;16(suppl): S38-S42.
5. Stroffolini T, Mele A, Tosti ME, et al.. The impact of the hepatitis B mass immunisation campaign on the incidence and risk factors of acute hepatitis B in Italy. J Hepatol. 2000;33: 980-985.
6. Fabris L, Baldo V, Baldovin T, et al.. Changing epidemiology of HCV and HBV infections in Northern Italy: a survey in the general population. J Clin Gastroenterol. 2008;42:527-532.
7. Stroffolini T, Sagnelli E, Almasio PL, et al.. Characteristics of liver cirrhosis in Italy: results from a multicenter national study. Dig Liver Dis. 2004;36:56-60. (Pubitemid 41122225)
8. Stroffolini T, Andreone P, Andriulli A, et al.. Characteristics of hepatocellular carcinoma in Italy. J Hepatol. 1998;29:944-952.
9. Wong JB, Koff RS, Tinè F, et al.. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med. 1995;122:664-675.
10. Niederau C, Heintges T, Lange S, et al.. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med. 1996;334:1422-1427.
11. Di Marco V, Lo Iacono O, Cammà C, et al.. The long-term course of chronic hepatitis B. Hepatology. 1999;30:257-264.
12. Manns MP. Current state of interferon therapy in the treatment of chronic hepatitis B. Semin Liver Dis. 2002; 22(suppl 1):7-13.
13. Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther. 2008; 28:167-177.
14. The EASL Jury. EASL International Consensus Conference on Hepatitis B 13-14 September, 2002, Geneva, Switzerland. Consensus statement (short version). J Hepatol. 2003;38: 533-540.
15. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507-539. Erratum in: Hepatology. 2007;45:1347.
16. Keeffe EB, Dieterich DT, Han SH, et al.. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol. 2006;4:936-962.
17. McMahon BJ. The natural history of chronic hepatitis B virus infection. Semin Liver Dis. 2004;24(suppl 1):17-22.
18. Raimondo G, Isgrò G, Caccamo G, et al.. Is there a downgrading in the alert about the hepatitis B virus infection in Italy? Dig Liver Dis. 2007;39:257-261.
19. Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis. 2003;23:47-58.
20. Perrillo R, Nair S. Hepatitis B. In: Boyer TD, Wright TL, Manns MP, eds. Zakim and Boyer's Hepatology. A Textbook of Liver Disease. 5th ed. Philadelphia, PA: Saunders-Elsevier; 2007:635-663.
21. Bruix J, Sherman M, Llovet JM, et al.. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-430.
22. Keeffe EB. Hepatitis B: explosion of new knowledge. Gastroenterology. 2007;133:1718-1728.
23. Iloeje UH, Yang HI, Jen CL, et al.. Predicting cirrhosis risk based on level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678-686.
24. Chen CJ, Yang HI, Su J, et al.. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65-73.
25. Chen G, Lin W, Shen F, et al.. Past viral load as a predictor of mortality an morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol. 2006;101: 1797-1803.
26. Kumar M, Sarin SK, Hissar S, et al.. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology. 2008; 134:1376-1384.
27. Tsang PS, Trinh H, Garcia RT, et al.. Significant prevalence of histologic disease in patients with chronic hepatitis B and mildly elevated serum alanine aminotransferase levels. Clin Gastroenterol Hepatol. 2008;6:569-574.
28. Liaw Y-F, Leung N, Guan R, et al.. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int. 2005;25:472-489.
29. Carosi G, Rizzetto M. Treatment of chronic hepatitis B: Recommendations from an Italian workshop. Dig Liver Dis. 2008;40:603-617.
30. Wang CC, Lim LY, Deubner H, et al.. Factors predictive of significant fibrosis in adults with chronic hepatitis B and normal serum ALT. J Clin Gastroenterol. 2008;42: 820-826.
31. Torre F, Basso M, Picciotto A, et al.. Clinical and virological survey of HBsAg positive patients in a single Italian region. Dig Liver Dis. 2008;40:A16-A17.
32. Niederau C. Epidemiology of hepatitis B in Germany. Med Klin (Munich). 2007;102:351-357.
33. Perrillo RP, Jacobson IM. Halting the natural history of hepatitis B viral infection: a paradigm shift. Semin Liver Dis. 2007;27(suppl 1):3-8.
34. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology. 2006;43:S173-S181.